Last reviewed · How we verify
Receipt of PCV20 (receipt-of-pcv20)
Receipt of PCV20 (generic name: receipt-of-pcv20) is a The main exposure of interest will be receipt of PCV20. drug developed by Pfizer Inc.. It is currently in preclinical development.
The main exposure of interest will be receipt of PCV20.
PCV20 is a small molecule intervention used to study its effectiveness in preventing all-cause pneumonia and lower respiratory tract infections. PCV20 is being studied in adults who have a higher chance of getting pneumonia.
-
Baseline preclinical → approval rate
+5.0pp
Industry-wide preclinical drugs reach approval ~5% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline. -
Big-pharma sponsor
+3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2036–2040 | — |
| EMA | EU | 2037–2041 | +0.7 yr |
| MHRA | GB | 2037–2041 | +0.7 yr |
| Health Canada | CA | 2037–2042 | +0.9 yr |
| TGA | AU | 2037–2042 | +1.2 yr |
| PMDA | JP | 2037–2042 | +1.5 yr |
| NMPA | CN | 2038–2043 | +2.3 yr |
| MFDS | KR | 2037–2042 | +1.4 yr |
| CDSCO | IN | 2037–2043 | +1.8 yr |
| ANVISA | BR | 2038–2043 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | receipt-of-pcv20 |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | The main exposure of interest will be receipt of PCV20. |
| Therapeutic area | Infectious Disease |
| Phase | preclinical |
Mechanism of action
PCV20 is a vaccine that helps your body's immune system prepare for potential pneumococcal infections. The vaccine contains small pieces of 20 different strains of pneumococcal bacteria (harmless fragments, not live bacteria) that are linked to a carrier protein. When you receive the vaccine, your immune system learns to recognize these bacterial pieces as invaders and develops antibodies and immune memory to fight them off. If you later encounter any of these 20 pneumococcal strains in real life, your immune system is already primed and ready to attack. This prevents the bacteria from establishing an infection or significantly reduces the severity of illness if infection does occur. Because PCV20 covers 20 different strains, it provides broader protection than earlier pneumococcal vaccines that only covered 13 strains. This vaccine is particularly important because pneumococcal bacteria can cause serious infections including pneumonia, meningitis, and bloodstream infections, especially in older adults and people with certain medical conditions. By receiving PCV20, you give your body the tools to prevent these potentially life-threatening infections before they start.
Approved indications
Pipeline indications
- Pneumonia — preclinical
Common side effects
Key clinical trials
- A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneu (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Receipt of PCV20 CI brief — competitive landscape report
- Receipt of PCV20 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Receipt of PCV20
What is Receipt of PCV20?
How does Receipt of PCV20 work?
Who makes Receipt of PCV20?
What is the generic name of Receipt of PCV20?
What drug class is Receipt of PCV20 in?
What development phase is Receipt of PCV20 in?
Related
- Drug class: All The main exposure of interest will be receipt of PCV20. drugs
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing